CHRISTOPHER TIKUM: Open Payments
NPI 1578269056 · EAST ORANGE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,955 in 191 payments from 12 companies in 2025. Trend: 2023 $590 · 2024 $1,500 · 2025 $2,955
Food & beverage: $2,944Education: $11
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 60 | $978 |
| Alkermes, Inc. | 36 | $677 |
| Neurocrine BioSciences, Inc. | 40 | $516 |
| ABBVIE INC. | 16 | $196 |
| E.R. Squibb & Sons, L.L.C. | 15 | $162 |
| Otsuka America Pharmaceutical, Inc. | 8 | $152 |
| Lundbeck LLC | 6 | $107 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Vanda Pharmaceuticals Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $32 |
Products named: CAPLYTA, ARISTADA, INGREZZA, REXULTI, VRAYLAR, COBENFY, HETLIOZ, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
